Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

PPCR: Registry for Pedi Patients Treated With Proton RT

Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

A Study of TAS-120 in Patients With Advanced Solid Tumors

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia

A Phase Ib/II Multicenter Open-label Study of BGB324 in Patients With AML or MDS

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

A Study of Parsaclisib in Combination With Ruxolitinib in Subjects With Myelofibrosis

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas

SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers

Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies

A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma

CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

A Study of ASN007 in Patients With Advanced Solid Tumors

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Study of Stereotactic Body Radiation Therapy for Oligometastatic Renal Cell Carcinoma

This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

MRx0518 and Pembrolizumab Combination Study

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Genetic Susceptibility to Bladder Cancer

Carboplatin and Bevacizumab for Recurrent Ependymoma

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

MAGE-A4ᶜ¹º³²T for Multi-Tumor

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

First-in-human Study of DS-1062a for Advanced Solid Tumors

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme

T Cell Immunotherapy for Advanced Ovarian Cancer

Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Neratinib HER Mutation Basket Study (SUMMIT)

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly AML and MDS

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA